Titlebook: Handbook for Venous Thromboembolism; Gregory Piazza,Benjamin Hohlfelder,Samuel Z. Goldh Book 2015 Springer International Publishing Switze

Tyler

書目名稱Handbook for Venous Thromboembolism影響因子(影響力)




書目名稱Handbook for Venous Thromboembolism影響因子(影響力)學(xué)科排名




書目名稱Handbook for Venous Thromboembolism網(wǎng)絡(luò)公開度




書目名稱Handbook for Venous Thromboembolism網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Handbook for Venous Thromboembolism被引頻次




書目名稱Handbook for Venous Thromboembolism被引頻次學(xué)科排名




書目名稱Handbook for Venous Thromboembolism年度引用




書目名稱Handbook for Venous Thromboembolism年度引用學(xué)科排名




書目名稱Handbook for Venous Thromboembolism讀者反饋




書目名稱Handbook for Venous Thromboembolism讀者反饋學(xué)科排名

違法事實

說笑

,Pathophysiology of Deep Vein Thrombosis and Pulmonary Embolism: Beyond Virchow’s Triad,flammation, and hypercoagulability. The extent of the PE, the patient’s underlying cardiopulmonary reserve, and compensatory neurohumoral adaptations determine the overall hemodynamic impact. The right ventricle (RV) plays a central role in PE pathophysiology. A sudden increase in RV afterload due t

暴發(fā)戶

Diagnosis of Deep Vein Thrombosis: Incorporating Clinical Suspicion with Laboratory Testing and Imatrategy that combines an assessment of clinical probability of the diagnosis with use of D-dimer testing and imaging when appropriate maximizes diagnostic accuracy. Venous ultrasound is the imaging test of choice for most patients with suspected DVT.

記憶

Contend

nutrition

Advanced Therapy for Venous Thromboembolism: Understanding the Role of Systemic Fibrinolysis, Catheary embolism (PE) syndromes. Advanced therapies for acute PE include systemic fibrinolysis, catheter-based “pharmacomechanical” intervention, and surgical pulmonary embolectomy. Choosing a particular advanced therapy depends on the individual patient’s risk for adverse outcomes due to VTE and for ma

我說不重要

NOVA

Anticoagulation for Venous Thromboembolism: Selecting the Optimal Parenteral and Oral Anticoagulantunfractionated heparin, low-molecular-weight heparin, fondaparinux, argatroban, bivalirudin, warfarin, and the non-vitamin K oral anticoagulants (NOACs) rivaroxaban, dabigatran, apixaban, and edoxaban. The NOACs represent a major advance in anticoagulation for VTE with superior safety and equivalent

amnesia

Long-Term Management of Venous Thromboembolism: Strategies for Reducing the Risk of Recurrence,optimal duration and drug regimen requires an individualized assessment of the patient’s long-term risk of recurrence as well as bleeding. Warfarin and non-vitamin K oral anticoagulants (NOACs) have been validated for extended duration anticoagulation to prevent recurrent unprovoked VTE. Aspirin als